Vertaling van "reduction of cardiovascular events " (Nederlands → Frans) :

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-bli Lancet 362 : 782-788(2003)
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-bl Lancet 362 : 782-788(2003)

Results from the Japanese KYOTO HEART study, presented in September at the European Society of Cardiology Congress, demonstrated that the addition of Diovan to a non-ARB-based treatment regimen for high blood pressure provided a significant 45% relative risk reduction in cardiovascular events, including stroke, over a conventional non-ARB treatment regimen.
Les résultats de l’étude japonaise KYOTO HEART, présentés au Congrès de la Société Européenne de Cardiologie, ont prouvé que l’adjonction de Diovan lors d’un traitement contre l’hypertension non basé sur les ARA a conduit à une réduction importante de 45% du risque relatif d’accidents cardiovasculaires, notamment cérébraux, par rapport à un traitement non ARA conventionnel.

Twee zeer grote trials, die wellicht meer klaarheid over dit onderwerp zullen kunnen brengen zijn nog lopende: ACCEPT-D (Aspirin and Simvastatin combination for Cardiovascular Events Prevention Trial in Diabetes) en ASCEND (A Study of Cardiovascular Events in Diabetes).
Deux très grands essais cliniques, qui apporteront certainement plus de clarté à ce sujet sont encore en cours: ACCEPT-D (‘Aspirin and Simvastatin combination for Cardiovascular Events Prevention Trial in Diabetes’) et ASCEND (‘A Study of Cardiovascular Events in Diabetes’).

Berger JS, Kranz MJ, Kittelson JM et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease. A meta-analysis of randomized trials.
Fowkes FG, Price JF, Stewart MCW et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.

De auteurs tonen zich eveneens bezorgd over deze verhoogde cardiovasculaire mortaliteit (‘The higher rate of fatal cardiovascular events with olmesartan . is of concern’).
Les auteurs ont également exprimé leur inquiétude devant cette mortalité cardiovasculaire accrue (‘The higher rate of fatal cardiovascular events with olmesartan . is of concern’).

Selected pharmaceutical pipeline projects Project/ Potential indication/ Planned Current News update Compound Disease area submissions Phase ACZ885 Refractory gout acute 2010 III - On track for 2010 submission flares Systemic onset juvenile 2011 III idiopathic arthritis Type 2 diabetes II ≥2014 Secondary prevention of ≥2014 III - Phase III start planned end 2010 cardiovascular events Afinitor Neuroendocrine tumors 2010 III - On track for 2010 submission
Projets pharmaceutiques importants en pipeline Indication potentielle/ Projet / domaine Soumissions Phase Mises à jour molécule thérapeutique prévues actuelle ACZ885 Crises aiguës de la goutte réfractaire 2010 III - En voie d’être soumis en 2010

Inhaled anticholinergics and risk of major cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
of major cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Bolland MJ, Avenell A, Baron JA et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis.
Bolland MJ, Grey A, Avenell A et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis.

J. Hypertension 21, 1771-1773 (2003) The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.
J. Hypertension 21, 1771- 1773 (2003) The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.

In addition, a fourth business for primary care medicines, including the cardiovascular portfolio, will be consolidated into four regional units (reduction from the current five units).
En outre, un quatrième secteur d’activité pour les médicaments destinés aux soins de santé primaires, comprenant le portefeuille cardiovasculaire, sera consolidé en quatre (cinq actuellement) unités régionales.